Drug Database
Back to search

Netherlands· NL-c391f0b36604

Luminity 150 microliter/ml oplossing voor dispersie voor injectie of infusie

A perflutren, phospholipid-mikrosphären product containing perflutren, registered in Netherlands by Lantheus EU Limited. The same ATC class is registered in 9 of our 19 countries.

ATC V08DA04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLuminity 150 microliter/ml oplossing …ATCV08DA04REGISTER NO.NL-c391f0b36604PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about perflutrenAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Perflutren, phospholipid-mikrosphären is registered in 9 of 19 countries.

Countries holding a registration under ATC V08DA04 (perflutren, phospholipid-mikrosphären), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 5 of them publish a price we can compare per daily dose
Search perflutren, phospholipid-mikrosphären products by name

Perflutren, phospholipid-mikrosphären · ATC V08DA04

9 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
PERFLUTREN
Manufacturer
Lantheus EU Limited
Country
Netherlands (NL)
ATC code
V08DA04
ATC class
Perflutren, Phospholipid-Mikrosphären
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/06/361

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

159 interactions on record for perflutren, phospholipid-mikrosphären.

Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check perflutren, phospholipid-mikrosphären against other medicinesHow interaction checks work

Perflutren, phospholipid-mikrosphären · interactions on record

159 records

  • 36 severe
  • 121 moderate
  • 2 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Perflutren, phospholipid-mikrosphären in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All perflutren, phospholipid-mikrosphären products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Optison
  • Iceland · Optison
  • Liechtenstein · Optison
  • Norway · Optison

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/41e25ffa-84e2-42b2-81b5-483f93b935c2
GET /v1/drugs/41e25ffa-84e2-42b2-81b5-483f93b935c2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispersie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/luminity-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Perflutren, phospholipid microspheres",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp72852",
  "excipients": [
    "1,2-DIPALMITOYL-SN-GLYCERO-3-FOSFAATNATRIUM",
    "COLFOSCERILPALMITAAT",
    "DINATRIUMWATERSTOFFOSFAAT 7-WATER (E 339)",
    "GLYCEROL (E 422)",
    "N-(METHOXYPOLYETHYLEENGLYCOL 5000 CARBAMOYL)-1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATIDYLETHANOLAMINENATRIUM",
    "NATRIUMCHLORIDE",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "PROPYLEENGLYCOL (E 1520)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "PERFLUTREN"
  ],
  "leaflet_url": null,
  "authorised_at": "2006/09/20",
  "procedure_number": "EMEA/H/C/000654",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/06/361",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about perflutren, phospholipid-mikrosphären.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console